Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1954944 | 0.91 | PRKCA (0.45) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL1956589 | 0.90 | PRKCA (0.36) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL1954406 | 0.90 | PRKCA (0.37) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL1956164 | 0.85 | SCN9A (0.41) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL1980990 | 0.83 | PTGDR2 (0.41) | PRKCAMMP12CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1954720 | 0.83 | PRKCA (0.46) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL1956510 | 0.82 | PLA2G1B (0.38) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL1981576 | 0.78 | SCN9A (0.40) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL1980588 | 0.78 | SCN9A (0.36) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL1980568 | 0.78 | PRKCA (0.39) | PRKCAMMP12NR1I2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331554-B1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | JANSSEN R & D IRELAND (IE) | 2013-03-06 | — | — | EP | disclosed |
| EP-2331554-B1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | JANSSEN R & D IRELAND (IE) | 2013-03-06 | — | — | EP | disclosed |
| US-8357687-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | TIBOTEC PHARMACEUTICALS (IE) | 2013-01-22 | — | — | US | disclosed |
| US-8357687-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | TIBOTEC PHARMACEUTICALS (IE) | 2013-01-22 | — | — | US | disclosed |
| US-8357687-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | TIBOTEC PHARMACEUTICALS (IE) | 2013-01-22 | — | — | US | disclosed |
| US-20110152279-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-06-23 | — | — | US | disclosed |
| US-20110152279-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-06-23 | — | — | US | disclosed |
| US-20110152279-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-06-23 | — | — | US | disclosed |
| WO-2010018233-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152279-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | IDO1, IDO2, ZC3HAV1 | PRKCA 3816/4885MMP12 3986/4885NR1I2 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.